Sight Sciences announced the launch of the Ergo-Series of the OMNI Surgical System in Europe, a technology that facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with open-angle glaucoma. The Ergo-Series was originally launched in the United States in March 2023, and since has been broadly adopted by surgeon users of OMNI due to its improved ergonomics and an optimized cannula tip that provides gentle and precise access to Schlemm’s canal. “We are pleased with all the positive feedback on the OMNI Ergo-Series from surgeons in the United States, and we are delighted to have now received CE Mark under the new EU Medical Device Regulation to market this enhanced version of our OMNI technology in Europe as well,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “We believe the improved handle ergonomics, simplified viscoelastic preparation, and new cannula tip design will be invaluable to our European partners, so we are excited to launch the technology at the European Society of Cataract and Refractive Surgeons Winter meeting this week in Frankfurt.” Professor Fritz Hengerer, Chief Medical Officer and Director Burgerhospital Eye Clinic in Frankfurt, said, “I am particularly impressed with the improved ergonomics and overall design enhancements of the OMNI Ergo-Series. These upgrades make the OMNI Surgical System even more user-friendly which could encourage surgeons to intervene earlier, when appropriate, to help delay disease progression, thus helping to preserve vision and potentially reduce the medication burden of patients with glaucoma.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SGHT:
- Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
- Sight Sciences Executive Compensation Adjustments for 2024
- Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
- Sight Sciences price target raised to $5 from $2.50 at Piper Sandler
- Sight Sciences sees FY23 revenue $80.9M-$81.1M, consensus $80.42M